Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
multiple myeloma - 1st line (L1), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-185, 2019 2.06 [0.93; 4.56]
2.06 [0.93 ; 4.56 ] KEYNOTE-185, 2019 1 0% 301 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-185, 2019 1.22 [0.67; 2.22]
1.22 [0.67 ; 2.22 ] KEYNOTE-185, 2019 1 0% 301 NA not evaluable DCRdetailed results KEYNOTE-185, 2019 0.80 [0.43; 1.46]
0.80 [0.43 ; 1.46 ] KEYNOTE-185, 2019 1 0% 301 NA not evaluable objective responses (ORR)detailed results KEYNOTE-185, 2019 1.07 [0.67; 1.71]
1.07 [0.67 ; 1.71 ] KEYNOTE-185, 2019 1 0% 301 NA not evaluable AE (any grade)detailed results KEYNOTE-185, 2019 1.40 [0.57; 3.44]
1.40 [0.57 ; 3.44 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-185, 2019 2.17 [1.36; 3.46]
2.17 [1.36 ; 3.46 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-185, 2019 1.64 [0.66; 4.08]
1.64 [0.66 ; 4.08 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-185, 2019 2.62 [1.45; 4.72]
2.62 [1.45 ; 4.72 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable SAE (any grade)detailed results KEYNOTE-185, 2019 1.84 [1.16; 2.92]
1.84 [1.16 ; 2.92 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-185, 2019 3.00 [0.60; 15.11]
3.00 [0.60 ; 15.11 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-185, 2019 2.91 [1.43; 5.93]
2.91 [1.43 ; 5.93 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 0.97 [0.02; 49.37]
0.97 [0.02 ; 49.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 5.94 [0.29; 119.61]
5.94 [0.29 ; 119.61 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 0.97 [0.02; 49.37]
0.97 [0.02 ; 49.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 3.93 [0.18; 87.94]
3.93 [0.18 ; 87.94 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 0.97 [0.02; 49.37]
0.97 [0.02 ; 49.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Rash TRAE (grade 3-4)detailed results Out of scale KEYNOTE-185, 2019 27.63 [1.62; 470.16]
27.63 [1.62 ; 470.16 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-185, 2019 0.97 [0.02; 49.37]
0.97 [0.02 ; 49.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.92 [0.79; 4.67]
1.92 [0.79 ; 4.67 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.64 [0.39; 7.01]
1.64 [0.39 ; 7.01 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-185, 2019 3.93 [0.18; 87.94]
3.93 [0.18 ; 87.94 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-185, 2019 0.97 [0.02; 49.37]
0.97 [0.02 ; 49.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-185, 2019 0.64 [0.11; 3.91]
0.64 [0.11 ; 3.91 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-185, 2019 10.03 [0.54; 185.37]
10.03 [0.54 ; 185.37 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-185, 2019 12.13 [0.67; 219.12]
12.13 [0.67 ; 219.12 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.64 [0.39; 7.01]
1.64 [0.39 ; 7.01 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-185, 2019 2.96 [0.30; 28.78]
2.96 [0.30 ; 28.78 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.04 [0.50; 2.20]
1.04 [0.50 ; 2.20 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.95 [0.07; 58.66]
1.95 [0.07 ; 58.66 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-185, 2019 1.31 [0.44; 3.89]
1.31 [0.44 ; 3.89 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-185, 2019 7.97 [0.42; 152.17]
7.97 [0.42 ; 152.17 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-185, 2019 6.04 [0.72; 50.82]
6.04 [0.72 ; 50.82 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-185, 2019 3.93 [0.18; 87.94]
3.93 [0.18 ; 87.94 ] KEYNOTE-185, 2019 1 0% 294 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-17 14:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 205
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
